G
Gregory P. Swanson
Researcher at Scott & White Hospital
Publications - 125
Citations - 6012
Gregory P. Swanson is an academic researcher from Scott & White Hospital. The author has contributed to research in topics: Prostate cancer & Radiation therapy. The author has an hindex of 24, co-authored 119 publications receiving 5448 citations. Previous affiliations of Gregory P. Swanson include Karolinska Institutet & University of Texas at Austin.
Papers
More filters
Journal ArticleDOI
Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical Trial
Ian M. Thompson,Catherine M. Tangen,Jorge Paradelo,M. Scott Lucia,Gary J. Miller,Dean A. Troyer,Edward M. Messing,Jeffrey D. Forman,Joseph L. Chin,Gregory P. Swanson,Edith D. Canby-Hagino,E. David Crawford +11 more
TL;DR: Adjuvant radiotherapy after radical prostatectomy for a man with pT3N0M0 prostate cancer significantly reduces the risk of metastasis and increases survival.
Journal ArticleDOI
Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial.
Ian M. Thompson,Catherine M. Tangen,Jorge Paradelo,M. Scott Lucia,Gary J. Miller,Dean A. Troyer,Edward M. Messing,Jeffrey D. Forman,Joseph L. Chin,Gregory P. Swanson,Edith Canby-Hagino,E. David Crawford +11 more
TL;DR: In men who had undergone radical prostatectomy for pathologically advanced prostate cancer, adjuvant radiotherapy resulted in significantly reduced risk of PSA relapse and disease recurrence, although the improvements in metastasis-free survival and overall survival were not statistically significant.
Journal ArticleDOI
Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study.
Jack Cuzick,Gregory P. Swanson,Gabrielle Fisher,Arthur R. Brothman,Daniel M. Berney,Julia Reid,David Mesher,V. O. Speights,Elzbieta Stankiewicz,Christopher S. Foster,Henrik Møller,Peter T. Scardino,Jorja D Warren,Jimmy Park,Adib Younus,Darl D. Flake,Susanne Wagner,Alexander Gutin,Jerry S. Lanchbury,Steven Stone +19 more
TL;DR: There is strong evidence that the CCP score is a robust prognostic marker, which, after additional validation, could have an essential role in determining the appropriate treatment for patients with prostate cancer.
Journal ArticleDOI
Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer
W. Robert Lee,James J. Dignam,Mahul B. Amin,Deborah Watkins Bruner,Daniel A. Low,Gregory P. Swanson,Amit Shah,David D'Souza,Jeff M. Michalski,Ian S. Dayes,Samantha A. Seaward,William A. Hall,Paul L. Nguyen,Thomas M. Pisansky,Sergio Faria,Yuhchyau Chen,Bridget F. Koontz,Rebecca Paulus,Howard M. Sandler +18 more
TL;DR: In men with low-risk prostate cancer, the efficacy of 70 Gy in 28 fractions over 5.6 weeks is not inferior to 73.8 Gy in 41 fractions over 8.2 weeks, although an increase in late GI/genitourinary adverse events was observed in patients treated with H-RT.
Journal ArticleDOI
Validation of a Cell-Cycle Progression Gene Panel to Improve Risk Stratification in a Contemporary Prostatectomy Cohort
Matthew R. Cooperberg,Jeffry P. Simko,Janet E. Cowan,Julia Reid,Azita Djalilvand,Satish Bhatnagar,Alexander Gutin,Jerry S. Lanchbury,Gregory P. Swanson,Steven Stone,Peter R. Carroll +10 more
TL;DR: The CCP score was validated to have significant prognostic accuracy after controlling for all available clinical and pathologic data, and may improve accuracy of risk stratification for men with clinically localized prostate cancer, including those with low-risk disease.